CHF Solutions Welcomes Industry Veteran Nestor Jaramillo as Chief Commercial Officer
EDEN PRAIRIE, Minn., May 06, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announces it has hired Nestor Jaramillo, Jr. as its new chief commercial officer, effective May 7, 2019.
“Nestor has been a key player in medical device commercialization for more than 20 years and has led commercial organizations in both startup and multinational companies,” said John Erb, CEO of CHF Solutions. “With Nestor in place, we look forward to enhancing our sales and marketing execution which will drive our revenue growth.”
Prior to joining CHF Solutions, Mr. Jaramillo was president and CEO of Innerspace Neuro Solutions, Inc., a Tustin, Calif.-based commercial-stage medical technology company that developed, manufactured and distributed an intracranial pressure monitoring system. He also worked in a variety of capacities at startup Transoma Medical, St. Jude Medical, and at Medtronic. In addition, he also spent seven years as a managing director of healthcare investment banking at both Cherry Tree & Associates and Craig-Hallum Capital, both in Minneapolis. He holds an engineering degree from the University of North Dakota and a Master of Business Administration from the University of St. Thomas in Minneapolis.
“I’m excited to work with an organization that is providing the medical community a unique approach to fluid management with the goal of improving clinical outcomes for patients, whether in the hospital or outpatient clinic setting,” said Mr. Jaramillo. “CHF Solutions is continually seeking new applications and venues for the Aquadex FlexFlow® ultrafiltration system and I look forward to working with the team to further expand our market presence and provide this life-changing therapy to the many patients who urgently need it.”
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company’s mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements relating to the company’s future sales and marketing. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTORS:Claudia Napal DraytonChief Financial Officer CHF Solutions, Inc.952-345-4205 email@example.com
MEDIAJules Abraham JQA Partners, Inc. 917-885-7378 firstname.lastname@example.org
Source: CHF Solutions, Inc.